Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Up 9% After Analyst Upgrade

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) rose 9% on Monday after Barclays raised their price target on the stock from $60.00 to $62.00. Barclays currently has an overweight rating on the stock. Tarsus Pharmaceuticals traded as high as $52.20 and last traded at $53.16. Approximately 140,704 shares traded hands during trading, a decline of 81% from the average daily volume of 750,498 shares. The stock had previously closed at $48.78.

Several other equities analysts have also issued reports on TARS. The Goldman Sachs Group lifted their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, November 15th. Oppenheimer upped their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $56.00.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. R Squared Ltd bought a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter valued at approximately $53,000. FMR LLC increased its holdings in Tarsus Pharmaceuticals by 236.6% in the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock valued at $166,000 after acquiring an additional 3,537 shares during the last quarter. Dark Forest Capital Management LP bought a new stake in Tarsus Pharmaceuticals in the 2nd quarter valued at $202,000. SG Americas Securities LLC lifted its stake in Tarsus Pharmaceuticals by 87.5% in the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock worth $238,000 after purchasing an additional 3,379 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Tarsus Pharmaceuticals by 64.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock valued at $241,000 after purchasing an additional 2,879 shares during the last quarter. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Trading Up 5.5 %

The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The stock has a market cap of $1.97 billion, a PE ratio of -13.50 and a beta of 1.02. The stock has a 50-day moving average price of $51.18 and a two-hundred day moving average price of $39.25.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.